A citation-based method for searching scientific literature

Stephen Zewinger, Jochen Reiser, Vera Jankowski, Dalia Alansary, Eunsil Hahm, Sarah Triem, Mira Klug, Stefan J Schunk, David Schmit, Rafael Kramann, Christina Körbel, Emmanuel Ampofo, Matthias W Laschke, Simina-Ramona Selejan, Anna Paschen, Tobias Herter, Susanne Schuster, Günther Silbernagel, Martina Sester, Urban Sester, Gunter Aßmann, Robert Bals, Gerhard Kostner, Willi Jahnen-Dechent, Michael D Menger, Lucia Rohrer, Winfried März, Michael Böhm, Joachim Jankowski, Manfred Kopf, Eicke Latz, Barbara A Niemeyer, Danilo Fliser, Ulrich Laufs, Thimoteus Speer. Nat Immunol 2020
Times Cited: 74







List of co-cited articles
681 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
677
21

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
17

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
569
17

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
17

Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Joseph L Witztum, Daniel Gaudet, Steven D Freedman, Veronica J Alexander, Andres Digenio, Karren R Williams, Qingqing Yang, Steven G Hughes, Richard S Geary, Marcello Arca,[...]. N Engl J Med 2019
174
16

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.
Jianjin Shi, Yue Zhao, Kun Wang, Xuyan Shi, Yue Wang, Huanwei Huang, Yinghua Zhuang, Tao Cai, Fengchao Wang, Feng Shao. Nature 2015
14

Targeting APOC3 in the familial chylomicronemia syndrome.
Daniel Gaudet, Diane Brisson, Karine Tremblay, Veronica J Alexander, Walter Singleton, Steven G Hughes, Richard S Geary, Brenda F Baker, Mark J Graham, Rosanne M Crooke,[...]. N Engl J Med 2014
277
13

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
Daniel Gaudet, Veronica J Alexander, Brenda F Baker, Diane Brisson, Karine Tremblay, Walter Singleton, Richard S Geary, Steven G Hughes, Nicholas J Viney, Mark J Graham,[...]. N Engl J Med 2015
331
13

The NLRP3 inflammasome: molecular activation and regulation to therapeutics.
Karen V Swanson, Meng Deng, Jenny P-Y Ting. Nat Rev Immunol 2019
13

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
12

Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2.
Thimoteus Speer, Lucia Rohrer, Przemyslaw Blyszczuk, Rukshana Shroff, Kira Kuschnerus, Nicolle Kränkel, Gabriela Kania, Stephen Zewinger, Alexander Akhmedov, Yi Shi,[...]. Immunity 2013
203
10

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Philip L S M Gordts, Ryan Nock, Ni-Huiping Son, Bastian Ramms, Irene Lew, Jon C Gonzales, Bryan E Thacker, Debapriya Basu, Richard G Lee, Adam E Mullick,[...]. J Clin Invest 2016
133
10

N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels.
Veronica J Alexander, Shuting Xia, Eunju Hurh, Steven G Hughes, Louis O'Dea, Richard S Geary, Joseph L Witztum, Sotirios Tsimikas. Eur Heart J 2019
89
10

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
10

Human Monocytes Engage an Alternative Inflammasome Pathway.
Moritz M Gaidt, Thomas S Ebert, Dhruv Chauhan, Tobias Schmidt, Jonathan L Schmid-Burgk, Francesca Rapino, Avril A B Robertson, Matthew A Cooper, Thomas Graf, Veit Hornung. Immunity 2016
368
9

Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.
Raimund Pechlaner, Sotirios Tsimikas, Xiaoke Yin, Peter Willeit, Ferheen Baig, Peter Santer, Friedrich Oberhollenzer, Georg Egger, Joseph L Witztum, Veronica J Alexander,[...]. J Am Coll Cardiol 2017
107
9

Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes.
Jenny E Kanter, Baohai Shao, Farah Kramer, Shelley Barnhart, Masami Shimizu-Albergine, Tomas Vaisar, Mark J Graham, Rosanne M Crooke, Clarence R Manuel, Rebecca A Haeusler,[...]. J Clin Invest 2019
44
15

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.
Toni I Pollin, Coleen M Damcott, Haiqing Shen, Sandra H Ott, John Shelton, Richard B Horenstein, Wendy Post, John C McLenithan, Lawrence F Bielak, Patricia A Peyser,[...]. Science 2008
457
9

Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.
Haibo Li, Yingchun Han, Rong Qi, Yuhui Wang, Xiaohong Zhang, Maomao Yu, Yin Tang, Mengyu Wang, Ya-Nan Shu, Wei Huang,[...]. Cardiovasc Res 2015
32
21

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
9

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
9

Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells.
Akio Kawakami, Masanori Aikawa, Peter Libby, Pilar Alcaide, Francis W Luscinskas, Frank M Sacks. Circulation 2006
147
9

The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation.
Nathan Kelley, Devon Jeltema, Yanhui Duan, Yuan He. Int J Mol Sci 2019
639
9

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
819
9

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Stephen J Nicholls, A Michael Lincoff, Michelle Garcia, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire,[...]. JAMA 2020
188
9

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Rebecca C Coll, Avril A B Robertson, Jae Jin Chae, Sarah C Higgins, Raúl Muñoz-Planillo, Marco C Inserra, Irina Vetter, Lara S Dungan, Brian G Monks, Andrea Stutz,[...]. Nat Med 2015
9

Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Giuseppe Danilo Norata, Sotirios Tsimikas, Angela Pirillo, Alberico L Catapano. Trends Pharmacol Sci 2015
103
8

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.
Jan Borén, M John Chapman, Ronald M Krauss, Chris J Packard, Jacob F Bentzon, Christoph J Binder, Mat J Daemen, Linda L Demer, Robert A Hegele, Stephen J Nicholls,[...]. Eur Heart J 2020
279
8

Clinical review on triglycerides.
Ulrich Laufs, Klaus G Parhofer, Henry N Ginsberg, Robert A Hegele. Eur Heart J 2020
112
8

Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Marja-Riitta Taskinen, Chris J Packard, Jan Borén. Curr Atheroscler Rep 2019
41
14

Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells.
Akio Kawakami, Masanori Aikawa, Pilar Alcaide, Francis W Luscinskas, Peter Libby, Frank M Sacks. Circulation 2006
203
8


Non-canonical inflammasome activation targets caspase-11.
Nobuhiko Kayagaki, Søren Warming, Mohamed Lamkanfi, Lieselotte Vande Walle, Salina Louie, Jennifer Dong, Kim Newton, Yan Qu, Jinfeng Liu, Sherry Heldens,[...]. Nature 2011
8

Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Aruna D Pradhan, Nina P Paynter, Brendan M Everett, Robert J Glynn, Pierre Amarenco, Marshall Elam, Henry Ginsberg, William R Hiatt, Shun Ishibashi, Wolfgang Koenig,[...]. Am Heart J 2018
178
8

The inflammasomes.
Kate Schroder, Jurg Tschopp. Cell 2010
8

The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease.
Yun-Hee Youm, Kim Y Nguyen, Ryan W Grant, Emily L Goldberg, Monica Bodogai, Dongin Kim, Dominic D'Agostino, Noah Planavsky, Christopher Lupfer, Thirumala D Kanneganti,[...]. Nat Med 2015
814
6

Major lipids, apolipoproteins, and risk of vascular disease.
Emanuele Di Angelantonio, Nadeem Sarwar, Philip Perry, Stephen Kaptoge, Kausik K Ray, Alexander Thompson, Angela M Wood, Sarah Lewington, Naveed Sattar, Chris J Packard,[...]. JAMA 2009
6

Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
Sandrine Caron, An Verrijken, Ilse Mertens, Carolina Huaman Samanez, Gisèle Mautino, Joel T Haas, Daniel Duran-Sandoval, Janne Prawitt, Sven Francque, Emmanuelle Vallez,[...]. Arterioscler Thromb Vasc Biol 2011
102
6

ANGPTL3 Deficiency and Protection Against Coronary Artery Disease.
Nathan O Stitziel, Amit V Khera, Xiao Wang, Andrew J Bierhals, A Christina Vourakis, Alexandra E Sperry, Pradeep Natarajan, Derek Klarin, Connor A Emdin, Seyedeh M Zekavat,[...]. J Am Coll Cardiol 2017
216
6


Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
Andres Digenio, Richard L Dunbar, Veronica J Alexander, Marcus Hompesch, Linda Morrow, Richard G Lee, Mark J Graham, Steven G Hughes, Rosie Yu, Walter Singleton,[...]. Diabetes Care 2016
91
6

High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation.
Katharina Lechner, Amy L McKenzie, Nicolle Kränkel, Clemens Von Schacky, Nicolai Worm, Uwe Nixdorff, Benjamin Lechner, Johannes Scherr, Oliver Weingärtner, Ronald M Krauss. Metab Syndr Relat Disord 2020
25
20

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Mark J Graham, Richard G Lee, Thomas A Bell, Wuxia Fu, Adam E Mullick, Veronica J Alexander, Walter Singleton, Nick Viney, Richard Geary, John Su,[...]. Circ Res 2013
243
6

Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
Julian C van Capelleveen, Sophie J Bernelot Moens, Xiaohong Yang, John J P Kastelein, Nicholas J Wareham, Aeilko H Zwinderman, Erik S G Stroes, Joseph L Witztum, G Kees Hovingh, Kay-Tee Khaw,[...]. Arterioscler Thromb Vasc Biol 2017
40
12

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Mark J Graham, Richard G Lee, Teresa A Brandt, Li-Jung Tai, Wuxia Fu, Raechel Peralta, Rosie Yu, Eunju Hurh, Erika Paz, Bradley W McEvoy,[...]. N Engl J Med 2017
320
6

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Frederick E Dewey, Viktoria Gusarova, Richard L Dunbar, Colm O'Dushlaine, Claudia Schurmann, Omri Gottesman, Shane McCarthy, Cristopher V Van Hout, Shannon Bruse, Hayes M Dansky,[...]. N Engl J Med 2017
396
6

Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study.
Peter G Scheffer, Tom Teerlink, Jacqueline M Dekker, Griët Bos, Giel Nijpels, Michaela Diamant, Piet J Kostense, Coen D A Stehouwer, Robert J Heine. Clin Chem 2008
48
10

Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease.
Brian A Ference, John J P Kastelein, Kausik K Ray, Henry N Ginsberg, M John Chapman, Chris J Packard, Ulrich Laufs, Clare Oliver-Williams, Angela M Wood, Adam S Butterworth,[...]. JAMA 2019
249
6

Gout-associated uric acid crystals activate the NALP3 inflammasome.
Fabio Martinon, Virginie Pétrilli, Annick Mayor, Aubry Tardivel, Jürg Tschopp. Nature 2006
6

Inflammatory caspases are innate immune receptors for intracellular LPS.
Jianjin Shi, Yue Zhao, Yupeng Wang, Wenqing Gao, Jingjin Ding, Peng Li, Liyan Hu, Feng Shao. Nature 2014
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.